RxDoctor Payments Data

Mansoor Ahmad, MD

Cardiovascular Disease · Peoria, ILNPI 1194059600

Payments from drug & device makers

$3,490in general payments, 2019–2025

Across 57 payments — averaging $61.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Johnson & Johnson$449
  • Boston Scientific$358
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$347
  • Novartis$261
  • Boehringer Ingelheim$220
  • plus $825 from 11 others

What the payments were for

  • Food & beverage$3,00186%
  • Education$49014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,490 in reported general payments places this provider in the 60th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$156,228
Medicare patients
1,798
Services billed
2,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$157,638
EntrestoSacubitril/Valsartan130$99,022
JardianceEmpagliflozin134$93,439
XareltoRivaroxaban35$32,448
Metoprolol Succinate228$2,668
Atorvastatin Calcium234$2,083
Furosemide301$1,566
Losartan Potassium150$1,282
Torsemide22$951
Metoprolol Tartrate86$710
Ezetimibe29$568
Potassium Chloride28$558
Hydrochlorothiazide135$519
ClopidogrelClopidogrel Bisulfate48$515
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$157,638189 claims
NovartisEntresto$261$99,022130 claims
Boehringer IngelheimJardiance$220$93,439134 claims
Johnson & JohnsonXarelto$449$32,44835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Peoria

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →